{"id":"W3030945835","doi":"10.1200/jco.2020.38.15_suppl.tps6589","title":"Phase III LEAP-010 study: first-line pembrolizumab with or without lenvatinib in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Lenvatinib; Pembrolizumab; Medicine; Internal medicine; Oncology; Head and neck squamous-cell carcinoma; Placebo; Clinical trial; Cancer; Head and neck cancer; Immunotherapy; Pathology; Thyroid cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001888396,0.001924384,0.00188428,0.0004492604,0.0004673122,0.00140409,0.001600673,0.002210562,0.008504566],"category_scores_gemma":[0.0008483656,0.0007480697,0.001428747,0.0003499397,0.0009513171,0.001076089,0.0003844908,0.004522608,0.002592944],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001168875,"about_ca_system_score_gemma":0.002145924,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001248926,"about_ca_topic_score_gemma":0.003383312,"domain_scores_codex":[0.9996628,0.0001541002,0.00001363296,0.00006007619,0.00003810569,0.00007134632],"domain_scores_gemma":[0.9993436,0.00009779435,0.0001122431,0.00004853436,0.00004408601,0.0003538162],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8127639,0.07712101,0.00256378,0.001496715,0.00146915,0.0002866448,0.0002264124,0.001601172,0.02834575,0.0003945098,0.009961296,0.06376965],"study_design_scores_gemma":[0.80437,0.1841373,0.004265854,0.00005683399,0.0004194142,0.0002057055,0.00004135979,0.000830155,0.002463173,0.0001781483,0.003005351,0.00002669981],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9692919,0.004702972,0.001045044,0.001423138,0.0005279896,0.01100181,0.005198953,0.0003989509,0.006409255],"genre_scores_gemma":[0.9530897,0.004447534,0.003393868,0.00355259,0.000423291,0.01326715,0.00739323,0.000107489,0.01432511],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008504566,"threshold_uncertainty_score":0.02845061,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1601881154732406,"score_gpt":0.4592504337238478,"score_spread":0.2990623182506071,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}